Nicolas Leupin - 04 Mar 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Reporting relationship: Former Chief Medical Officer
Issuer ticker: NVCR
Reported as of: 04 Mar 2026
Net transaction value: -$14,636
SEC form: 4
Accepted by SEC: 05 Mar 2026, 16:33:41 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: Steven Robbins, as attorney in fact for Leupin, Nicolas

Key filing fact

Nicolas Leupin filed Form 4 for NovoCure Ltd (NVCR) on 05 Mar 2026.

Key facts

This page summarizes Nicolas Leupin's Form 4 filing for NovoCure Ltd (NVCR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 16:33.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$14,636.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002007766 Primary reporting owner

Leupin Nicolas

Relationship: Former Chief Medical Officer
Address: C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE
Signature: Steven Robbins, as attorney in fact for Leupin, Nicolas
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCR transaction

Ordinary Shares

Sale

Transaction value: $14,636
Shares: -1,100
Change %: -1.1%
Price: $13.31
Shares after: 102,979
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.